Dolat Capital Broker Research reports

UPL Ltd's 2QFY21 earnings were ahead of our estimates, Sales/EBITDA grew by 14.4/15.2% YoY to Rs 89.3/16.6bn (D.est: Rs 83.8/15.7bn). APAT grew by 55% YoY to Rs 6.47bn. Sales growth was driven by a 19% volume growth across geographies....

Laurus reported robust 2Q beating our estimates primarily driven by stellar growth in formulations. Though majority growth is led by ARV tender based opportunities, leveraging its backward integration, Laurus has demonstrated commendable execution capability as the growth is volume led without any one-offs. Management remained confident of growth sustenance in 2H as well. In order to supplement future growth, Laurus has undertaken a massive capex program (Rs12bn) of which Rs5bn is allocated...

Suven Pharma reported soft 2Q. Revenues declined 13% YoY (flattish QoQ) with EBITDA margins at 41% (down 500bps YoY and 600bps QoQ). Lower revenues from specialty chemicals segment impacted margins. Further, lower profit share from Rising Pharma also impacted profits (down 20% YoY and QoQ). Nonetheless, management reiterated its guidance of 15% growth in top-line and 15-20% growth in bottom-line with EBITDA margins at 40%+ for FY21. This implies a robust 2H. Suven is on track in launching molecules (two in specialty chemicals over FY21-22 and one in pharma) in...

Navin Fluorine International Ltd (NFIL IN) reported a stellar 2QFY21 performance. Sales/EBITDA/PAT beat our estimates as Sales grew by 16.8% YoY to Rs 3.19bn (D.est: Rs 2.56bn)....

Intellect Design (INDA) reported 7.6% YoY growth in its revenues to $50.1mn ahead of DE at $49mn and significant turnaround on EBIT margins at 19% (up 400bps QoQ, was loss making in YoY period) in Q2FY21, beating our expectations. Commentary remains confident on sustaining revenue traction in the near future, given its strong deal win momentum (6 digital wins & 4 large deal wins), order book traction (up 8.5% YoY to Rs11.9bn), large funnel (pursuit $540mn) and strong recurring revenues (up 25% on TTM basis)...

Hero MotoCorp (HMCL) 2QFY21 numbers were broadly in line estimates. EBITDA increased by 17% YoY to Rs.12.8bn with margin at 13.7% (-81bps YoY). Increase in RM prices was offset by cost control measures and better operating leverage. The management sounded positive on domestic sales outlook with demand back to pre Covid level, expecting momentum to continue into the festive season. Festive sales have started off well for the company and retail sales reached 96% of last year during the Navratri period...

Driven by increasing preference for personal mobility, better financing availability and strong rural pick up, MSIL printed strong numbers in Q2FY21. EBITDA grew 20% YoY to Rs. 19.3bn with expanded margin at 10.3% (+86bps YoY) led by lower discounts ( Rs 17.3k/vehicle vs Rs.25k in 2Q last year) and cost control measures, partially offset by commodity inflation and adverse FX movement. PV demand has recovered in the past 2-3 months and dealer confidence has improved materially after strong Navratri sales, this...

The company reported a consolidated sales growth of 27.6% YoY to Rs 11.5bn. A strong sales growth in the CSM business (up 25% YoY to Rs 7.98bn) coupled with improving contribution from ISAGRO (Rs 996mn from domestic business, Rs 109mn from exports) led to a beat on our sales estimate of Rs 10.5bn. EBITDA growth of 45.5% YoY to Rs 2.8bn came in from an improvement in gross margins of 170bps YoY with improved business mix and product mix coupled with easing input costs....

NIM was sequentially higher by 30 bps to 2.86% due to lower slippages at 2% (including standstill NPAs) and improved spreads. Without standstill on NPAs, gross NPAs would be at 9.33% against...

V guard saw flat sales at Rs6.2bn, while EBIDTA was down 5% YoY at Rs739mn with EBIDTA margins were down 54bps YoY at 12%. PAT was down 13% at Rs500m. Cash generated from operations was strong at in 1HFY21 at Rs3.2bn vs Rs1.5bn YoY, as working capital has improved...